Abstract: This invention provides a process for preparing sodium ferric gluconate complex in sucrose using the following steps: a) combining a ferric salt solution with a weak alkali chosen from the group consisting of alkaline earth metal and ammonium salts, such as sodium carbonate, sodium bicarbonate, lithium carbonate, potassium carbonate, potassium bicarbonate, ammonium carbonate, ammonium bicarbonate and mixtures thereof, to form the ferric oxyhydroxide; b) combining ferric oxyhydroxide and sodium gluconate in solution to yield the sodium ferric gluconate complex; c) isolating the sodium ferric gluconate complex; and d) combining the sodium ferric gluconate with sucrose in solution to yield the desired sodium ferric gluconate complex in sucrose.

Abstract: A compound of formula wherein W, V, R1, R5, R2, R3 and R4 have various meanings, a process for their production and their use as a pharmaceutical.

Abstract: The present invention relates to a process for the production of clarithromycin from an aqueous medium in anhydrous form and in the form of a hydrate.

Abstract: The use of a metabotropic glutamate receptor mGluR7 agonist for the facilitation of neurotransmitter release from a nerve ending and the treatment of neurological conditions, including epilepsy. Transgenic knockout non-human mammals are provided which lack the mGluR7 gene, suitable for studying mGluR7 and modulators thereof as well as epilepsy. Specifically provided is a transgenic mouse homozygous for an inactivated endogenous mGlu7 gene which exhibits symptoms of epileptic seizures.

Abstract: The present invention provides processes for the production of a compound of formula I wherein X, R1 and R2 are substituents conventional in cephalosporin chemistry; especially a compound of formula I is ceftrixone, cefotaxime; e.g., in the form of a salt.

Abstract: Erythromycin A oxime in the form of a hemihydrate.

Abstract: The present invention relates to a method for producing dendritic cells from human hematopoietic progenitor cells by obtaining a cell sample that includes human progenitor cells and culturing the cell sample under plasma-free and serum-free conditions in the presence of a combination of cytokines to produce dendritic cells, where the combination of cytokines include TGF-&bgr;1.

Abstract: One of the problems facing transplantation procedures today is the availability of organs suitable for transplantation. A way around the lack of organs, it to harvest organs from animals. However, immune reactions between discordant donor and recipient mammals presents a major obstacle in such transplantation procedures. The production of transgenic non-human mammals expressing a DNA sequence encoding an homologous complement restriction factor or factors of a discordant mammalian species such that the expression of the DNA sequence would prevent xenograft rejection by the host mammal's immune system would provide organs, tissues and cells for transplantation.

Abstract: A process for increasing the diastereoisomeric ratio (B/A+B), wherein B is the more apolar and A is the more polar of two diastereoisomers, of a mixture of diastereoisomers of a compound of formula the diastereoisomers being with respect to the carbon atom marked with a star in formula I, comprising treating a mixture of diastereoisomers of a compound of formula I with alcohol and water and isolating the precipitated compound of formula I in an increased diastereoisomeric ratio (B/A+B) of 0.5 to 0.6.

Abstract: Conventionally, animal tissue from one species can only be transplanted into another species when the species are concordant; otherwise, hyperimmune rejection ensues. In this invention, donor tissue is modified, for example by being transgenic, to express or otherwise be in association with one or more substances, referred to as homologous complement restriction factors (HCRFs), which are active in the recipient species to prevent the complete activation of complement and therefore rejection. The invention is in part based on the discovery that the alternative pathway of complement activation, rather than the classical pathway, is responsible for hyperacute discordant xenograft rejection.

Abstract: The present invention relates to a nucleic acid molecule which codes for the cephalosporin acetylesterase from Bacillus subtilis ATCC 6633 (DSM 11909), vectors and host cells which comprise such a nucleic acid molecule, a process for the recombinant preparation of cephalosporin acetylesterase from B. subtilis ATCC 6633 (DSM 1 1909) using said nucleic acid molecule, and a process for preparing 3-deacetylcephalosporin compounds.

Abstract: Agglomerates of &bgr;-lactam antibiotics, such as penicilllin V potassium, amoxicillin trihydrate, cephalexin monohydrate, which are suitable for direct tablet formation.

Abstract: A compound useful as an anti-bacterial agent, having the formula wherein R2 together with the nitrogen atom to which it is attached forms a cyclic aminoguanidine group or derivative thereof as defined

Abstract: The present invention provides a freeze dried pharmaceutical composition comprising hirudin, potassium phosphate and a sugar.

Abstract: A process for the production of azithromycins by methylation of the nitrogen atom in position 9 of the ring structure in 9-deoxo-9a-aza-9a-homoerythromycins in the presence of formaldehyde and in the presence of a reducing agent in non-halogenated solvent; and azithromycin which is free from halogenated organic solvent in a stable anhydrous form; or in the form of a solvate with non-halogenated solvent with the exception of water.

Abstract: A process for the production of a 3-vinylcephalosporin compound of formula I wherein R1 and R2 denote hydrogen or an organic group by a Wittig reaction reacting first a compound of formula II with a compound of formula P(R4)3 or P(OR4)3 to produce a compound of formula III and secondly reacting the compound of formula III with a weak base of formula or of formula R10—COO−W+ wherein R5 is hydrogen, alkly or aryl and R6 and R7 are each an activated group of formula —COOR8, —CN, —SO2R8, —COR8 or —CON(R8)2; or R5 and R8 are each aryl and R7 is an activated group of formula —COOR8, —CN, —SO2R8, —COR8 or —CON(R8)2, W+ is an alkali metal cation and R10 is alkyl or aryl to produce a compound of formula IV and finally reacting a compound of formula IV with a compound of formula V to produce a compound of formula I.

Abstract: The isolated nucleic acid encoding human vanilloid receptor, said receptor, its preparation, cells expressing said receptor and an assay for testing compounds for their potential to decrease pain in human are disclosed. The receptor is involved in detection of noxious stimuli in mammalian organisms.

Abstract: A polylactide in a purified state, which meets the requirements of the color strengths of reference solutions B2-B9 of the brown color test of the European Pharmacopoeia, 2nd Edition (1980) part I, Section V, 6.2 and containing one or more metals in cationic form, the metal ion(s) having a concentration of at most 10 ppm. The polylactide is especially suitable for use as microparticles or implants, and contains preferably a hydrophilic drug, like octreotide or a lipophilic drug like bromocriptine.

Abstract: Transdominant repressors of viral gene phenotypic expression derived from the rev gene product of HIV-1 or the rex gene product of HTLV-1 and corresponding mutated genes, having the capability of repressing the Rev function in HIV-1 and/or the Rex function in HTLV-I and HTLV-II and, in some cases, both the Rev and the Rex function and are, therefore, active in more than one viral species. Such transdominant viral mutants are useful as anti-viral agents to, for example protect cells against the deleterious effects of viral, e.g. HIV-1, infection.

Abstract: A catheter or ostomy tube placement tip is comprised of a tapered, substantially conical head portion and a cylindrical body or stem portion centrally attached to the base thereof. The cylindrical base fits snugly within the lumen of a catheter or ostomy tube such as a ostomy or jejunal feeding tube and its tapered design allows for the insertion and placement of the tube within the lumen of the stomach or other body cavity through an opening or ostomy. Once properly placed, the tip is discharged from the end of the tube so that it is dissolved by human body fluids and is excreted.